Primary Peritoneal Carcinoma
149
18
33
64
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
32 trials with published results (21%)
Research Maturity
64 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.1%
21 terminated out of 149 trials
75.3%
-11.3% vs benchmark
9%
14 trials in Phase 3/4
50%
32 of 64 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 64 completed trials
Clinical Trials (149)
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
National Cancer Institute "Cancer Moonshot Biobank"